Anupam Rasayan India Ltd has reported its financial results for the quarter and year ended March 31, 2026. The company recorded a standalone net profit of INR 1,613.96 million for FY26. Furthermore, the Board has recommended a final dividend of INR 1.5 per share (15% of face value) and announced the strategic acquisition of up to a 74.20% equity stake in Bliss GVS Pharma Limited to bolster its market position.
Annual Financial Performance
For the financial year ended March 31, 2026, Anupam Rasayan India Ltd achieved a standalone revenue from operations of INR 16,755.67 million. The standalone net profit after tax stood at INR 1,613.96 million. On a consolidated basis, the company reported a robust annual revenue of INR 23,654.55 million, with a consolidated net profit attributable to the owners of the company at INR 1,701.21 million.
Strategic Acquisition and Funding
In a major strategic move, the Board has approved the acquisition of up to 74.20% of the total paid-up share capital and control of Bliss GVS Pharma Limited, a publicly listed pharmaceutical company. This acquisition is expected to significantly expand the company’s capabilities. Additionally, the Board has approved raising INR 160 crore through the private placement of 16,000 secured, rated, unlisted, redeemable, non-convertible debentures (NCDs).
Dividend and Governance Updates
The Board of Directors has recommended a final dividend of INR 1.5 per equity share, reflecting a 15% payout on the face value of INR 10 per share, subject to shareholder approval at the upcoming 23rd Annual General Meeting. In other organizational updates, the company announced the resignation of Mr. Vishal Thakkar from his position as Deputy Chief Financial Officer and Key Managerial Personnel, effective immediately.
Operational Highlights
The company continues to focus on its core business segment of custom synthesis and manufacturing of specialty chemicals. During the year, the company also successfully consummated the acquisition of a 100% equity stake in Jayhawk Fine Chemicals Corporation in the U.S., a move that aligns with its global growth strategy. The management is currently in the process of finalizing purchase price allocations for this acquisition to ensure accurate financial reporting.
Source: BSE
